Clinical trial
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients…
NCT00112294 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00112294 |
|---|---|
| Title | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
| Official title | A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin, Cetuximab |
| Enrollment | 755 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2008 |
| First posted | Jun 2, 2005 |
| Last update posted | Dec 24, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: